NICE recommends ranibizumab

Article

The National Institute for Health and Clinical Excellence (NICE) recommends the use of ranibizumab for patients with diabetic macular oedema (DME).

The National Institute for Health and Clinical Excellence (NICE) recommends the use of ranibizumab for patients with diabetic macular oedema (DME).

Ranibizumab, the only licensed anti-VEGF treatment for DME, has been issued positive draft guidance from NICE. Patients could soon benefit from the treatment- which could restore vision, prevent visual loss and maintain visual improvement.

Novartis has previously conducted a number of clinical trials on the DME treatment and concluded that the likelihood of gaining 10 or more letters of vision doubled compared to using a laser. With laser therapy three times as many patients could lose vision compared to those who were administered ranibizumab.

The Final Appraisal Document for ranibizumab is expected to be completed by the end of this year and will ensure that as many patients as possible have access to ranibizumab.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.